🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsTirzepatide (Mounjaro / Zepbound)Eli Lilly patient assistance programs — my results so far Page 3

Eli Lilly patient assistance programs — my results so far

Dr.DermMIA Sun, Nov 24, 2024 at 2:22 AM 12 replies 1,727 viewsPage 3 of 3
DebRD_ATL
Senior Member
1,678
7,890
Feb 2024
Atlanta, GA
Nov 27, 2024 at 8:41 PM#11
Dr.ObesityLA said:
sarah.morrison said: ...regarding the discontinuation data for cost and coverage...

Insurance coverage hack for cost and coverage: if your insurance denies brand Wegovy/Ozempic, consider these alternatives:

  1. Prior authorization appeal with peer-to-peer review
  2. Manufacturer copay card (for commercial insurance)
  3. Patient assistance programs (Novo Nordisk, Eli Lilly)
  4. Compounded medication from a 503B pharmacy ($148/month)
  5. Canadian pharmacy (requires prescription, ~40-60% savings)

Don't let cost prevent access to effective treatment. There are options at every price point.

Last edited: Nov 28, 2024 at 12:41 AM
27 0BiostatsBrad, PeptideSynthNJ, Dr.KarenChen and 24 others
Reply Quote Save Share Report
mike_mealprep
Member
412
1,890
Jul 2024
Chicago, IL
Nov 30, 2024 at 1:22 PM#12
SleepFixSam said:
Financial impact of cost and coverage weight loss beyond medication cost: Groceries: SAVED $229/month (eating less) Restaurants: SAVED $199/month…

Genuinely useful, thank you. I had the facts and not the framework. Sending this to two other people who asked me the same thing last week.

Last edited: Nov 30, 2024 at 7:22 PM
28 1newstart_MO, mia_MS2, LeilaHI and 25 others
Reply Quote Save Share Report
KarenAZ_mom
Member
567
2,567
Aug 2024
Scottsdale, AZ
Dec 3, 2024 at 6:04 AM#13
Dr.ObesityLA said:
sarah.morrison said: ...regarding the discontinuation data for cost and coverage...
Dr.ObesityLA said:
...my insurance denied cost and coverage coverage because...

Insurance denial is the single biggest barrier to GLP-1 access. Let me share the appeal framework that worked for me and several community members:

  1. Document medical necessity (BMI, comorbidities, failed alternatives)
  2. Reference clinical practice guidelines (AGA, AACE, Endocrine Society)
  3. Cite cost-effectiveness data (preventing diabetes/surgery saves money long-term)
  4. Request peer-to-peer review between your doctor and the plan's medical director
  5. File external appeal with your state insurance department if internal appeal fails

Don't accept the first denial. The appeal process exists for a reason.

29 2bri_stats, pete_manc_UK, anna.melb_AU and 26 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
quinn_sf
Member
489
2,123
Jun 2024
San Francisco, CA
Dec 5, 2024 at 10:48 PM#14
Dr.DermMIA said:
Denied on prior authorisation twice, approved on the third attempt after a peer-to-peer, and the only thing that changed was who was doing the…

Insurance update relevant to cost and coverage: I just got my prior auth approved through Aetna after 3 attempts.

What finally worked: a letter from my endocrinologist documenting BMI history (>3 years), failed diet attempts, comorbidities (sleep apnea + prediabetes), and referencing the SURMOUNT trial data.

If your PA keeps getting denied, don't give up. Request a peer-to-peer review between your doctor and the insurance medical director. That's what finally broke through for me.

Last edited: Dec 6, 2024 at 4:48 AM
30 3andrew_nyc, Dr.EndoEP, GraceAZ_72 and 27 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Dec 8, 2024 at 3:33 PM#15

Moderator note: good thread. Keeping it here rather than moving it, because the question is general enough to be useful.

31 4PurityPaulOR, MaxMetOK, MounjBrad and 28 others
Reply Quote Save Share Report

Similar Threads

SURMOUNT-5: Tirzepatide vs semaglutide head-to-head — full results11 replies
SURPASS 1-5 program: tirzepatide T2DM efficacy data compilation6 replies
Tirzepatide dual agonism: GIP + GLP-1 synergistic mechanism18 replies
5mg → 10mg → 15mg titration — clinical guidance and real-world data8 replies
Zepbound insurance coverage — payer-by-payer breakdown 20268 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register